The response to KRASi is associated with on‐treatment tumor microenvironment (TME) remodeling characterized by increased effector T‐cell infiltration, anti‐tumor M1‐macrophage repolarization, and natural killer (NK) cell recruitment,[13] which increase susceptibility to immunotherapies following KRAS inhibition. Here, KRAS is linked to neoplasm.